Viatris Inc. filings document the reporting record of a global healthcare company whose common stock trades on Nasdaq under VTRS. Form 8-K disclosures cover operating results, guidance and material events, including leadership transitions, restructuring actions from an enterprise-wide strategic review, bylaw amendments and shareholder-meeting matters.
Proxy statements describe board oversight, executive compensation, shareholder voting proposals, director nominations and governance practices. The filings also provide formal records for Viatris' capital return activity, strategic priorities, pipeline and product references, and the company's history as the combination of Mylan with Pfizer's Upjohn business.
Viatris Inc. reported stronger first-quarter 2026 results, with clear growth on a non-GAAP basis and reaffirmed full-year guidance. Total revenues were $3.5 billion, up 8% reported and 3% operationally versus first-quarter 2025, driven largely by Greater China. Adjusted EBITDA reached $1.0 billion, up 14%, while adjusted EPS rose to $0.59, up 18%. U.S. GAAP net earnings were $176 million, compared with a $3.0 billion loss a year earlier that included a large goodwill impairment. Operating cash flow was $388 million and free cash flow $348 million, both below last year, though free cash flow excluding transaction- and restructuring-related costs was $459 million. Management reaffirmed 2026 guidance, including total revenues of $14.45–$14.95 billion, adjusted EBITDA of $4.15–$4.45 billion, adjusted EPS of $2.33–$2.47, and free cash flow excluding transaction- and restructuring-related costs of $1.95–$2.35 billion.
Davis Selected Advisers files Amendment No. 7 to a Schedule 13G/A reporting 78,211,191 shares of Viatris Inc. common stock, representing 6.8% of the class as disclosed. The filing shows sole voting power for 75,605,333 shares and sole dispositive power for 78,211,191 shares; the ownership figures are tied to the reporting period 03/31/2026.
Viatris Inc. announced a planned Chief Financial Officer transition. Theodora “Doretta” Mistras will step down as CFO effective May 8, 2026, remaining employed until May 22, 2026 to support the handover, and her departure is stated as unrelated to any disagreements over accounting, financial reporting, internal controls or operations.
The Board appointed Paul Campbell, the current Chief Accounting Officer and Corporate Controller, as interim CFO effective May 8, 2026 while it searches for a permanent successor. Mistras will receive a pro rata 2026 bonus based on actual performance (capped at target) but no severance or equity vesting, and must sign a release and comply with restrictive covenants. Viatris also reiterated that it will release first‑quarter 2026 results on May 7, 2026 and hold a conference call at 8:30 a.m. ET.
Viatris Inc reports institutional ownership disclosure: Vanguard Capital Management filed a Schedule 13G reporting beneficial ownership of 84,807,083 shares of Viatris common stock, representing 7.36% of the class as of 03/31/2026. The filing shows sole dispositive power over 84,807,083 shares and sole voting power over 10,090,452 shares. The filing states these holdings reflect securities managed across Vanguard affiliates and funds. Signature on the form is dated 04/30/2026.
Viatris Inc Chief Commercial Officer Corinne Le Goff reported routine equity compensation activity tied to previously granted awards. On April 15, 2026, 39,344 restricted stock units and 3,643.8335 related dividend equivalent units vested and were converted into the same number of common shares.
The company withheld 19,067 common shares at $13.86 per share to cover associated tax liabilities, a non-market, tax-withholding disposition rather than an open-market sale. After these transactions, Le Goff holds 107,135 shares of Viatris common stock directly.
Viatris Inc. presents its 2026 proxy statement and notice of annual meeting, combining a performance review with key voting items for shareholders. In 2025 the company generated $14.3 billion in total revenues, returned more than $1 billion to shareholders via dividends and buybacks, and completed 60 regional business development transactions, including acquiring Aculys Pharma in Japan.
The proxy highlights five positive Phase 3 data readouts, a pipeline that includes selatogrel and cenerimod, and a global footprint delivering more than 70 billion doses of medicine across over 165 countries and territories in 2025. It also describes an enterprise‑wide strategic review aimed at optimizing structure, resource allocation and efficiency to support long‑term growth.
Shareholders are asked to elect 13 directors, approve on a non‑binding basis 2025 compensation for named executive officers, and ratify Deloitte & Touche LLP as auditor for 2026. Governance themes include an independent Chair, 12 of 13 director nominees classified as independent, formation of a Strategic Review Committee, and continued board refreshment, with seven new directors appointed since December 2022. The filing notes strong shareholder engagement and that the 2025 Say‑on‑Pay proposal received approximately 95% support.
The Vanguard Group filed Amendment No. 3 to a Schedule 13G/A reporting 0% ownership of Viatris Inc. Common Stock as of the amendment. The filing explains an internal realignment effective January 12, 2026 that disaggregated certain subsidiaries and business divisions from The Vanguard Group, Inc., and states those entities will report beneficial ownership separately.
The Schedule indicates Amount beneficially owned: 0 and sole and shared voting and dispositive powers: 0. The filing is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026.
Viatris Inc officer Paul Campbell reported an open-market sale of 21,350 shares of common stock at a weighted average price of $13.2805 per share. After this sale, he directly holds 366,288 shares, plus 318 shares held indirectly through a 401(k) plan, indicating he retains a substantial position.